Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $52 to $60.
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $52 to $60.